StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3033% below fair value
$79.32−0.87 (-1.08%)

Close on Nov 20, 2026Market cap $29.58BP/E 31.2Yield –

DexCom gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

DexCom's gross profit for the twelve months ending Sep 30, 2026 was $3.24B, up 21.5% year over year. For fiscal 2025 it was $2.80B, up 14.9% from the year before. Over ten years it grew 26.0% a year on average. The highest annual figure on record is $2.80B in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.80B+14.9%
FY2024Dec 31, 2024$2.44B+6.5%
FY2023Dec 31, 2023$2.29B+21.5%
FY2022Dec 31, 2022$1.88B+12.1%
FY2021Dec 31, 2021$1.68B+31.3%
FY2020Dec 31, 2020$1.28B+37.4%
FY2019Dec 31, 2019$931.50M+40.3%
FY2018Dec 31, 2018$663.90M+34.9%
FY2017Dec 31, 2017$492.10M+30.0%
FY2016Dec 31, 2016$378.40M+35.9%
FY2015Dec 31, 2015$278.40M+57.9%
FY2014Dec 31, 2014$176.30M+76.1%
FY2013Dec 31, 2013$100.10M+114.8%
FY2012Dec 31, 2012$46.60M+29.8%
FY2011Dec 31, 2011$35.90M+95.1%
FY2010Dec 31, 2010$18.40M+402.6%
FY2009Dec 31, 2009$3.66M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$864.40M+18.2%
Q2 FY2026Jun 30, 2026$830.00M+20.5%
Q1 FY2026Mar 31, 2026$750.30M+27.4%
Q4 FY2025Dec 31, 2025$792.70M+20.9%
Q3 FY2025Sep 30, 2025$731.40M+23.2%
Q2 FY2025Jun 30, 2025$688.80M+9.9%
Q1 FY2025Mar 31, 2025$589.00M+4.8%
Q4 FY2024Dec 31, 2024$655.80M-0.1%
Q3 FY2024Sep 30, 2024$593.80M-4.7%
Q2 FY2024Jun 30, 2024$626.70M+14.7%
Q1 FY2024Mar 31, 2024$561.90M+21.5%
Q4 FY2023Dec 31, 2023$656.60M+21.3%
Q3 FY2023Sep 30, 2023$623.30M+26.1%
Q2 FY2023Jun 30, 2023$546.40M+21.6%
Q1 FY2023Mar 31, 2023$462.60M+16.2%
Q4 FY2022Dec 31, 2022$541.30M+14.5%
Q3 FY2022Sep 30, 2022$494.20M+10.6%
Q2 FY2022Jun 30, 2022$449.50M+7.8%
Q1 FY2022Mar 31, 2022$398.10M+15.8%
Q4 FY2021Dec 31, 2021$472.60M+18.4%
Q3 FY2021Sep 30, 2021$446.90M+31.3%
Q2 FY2021Jun 30, 2021$417.10M+46.8%
Q1 FY2021Mar 31, 2021$343.90M+34.1%
Q4 FY2020Dec 31, 2020$399.10M+29.0%
Q3 FY2020Sep 30, 2020$340.40M+37.9%
Q2 FY2020Jun 30, 2020$284.10M+37.6%
Q1 FY2020Mar 31, 2020$256.50M+52.0%
Q4 FY2019Dec 31, 2019$309.30M+38.8%
Q3 FY2019Sep 30, 2019$246.90M+46.4%
Q2 FY2019Jun 30, 2019$206.50M+34.4%
Q1 FY2019Mar 31, 2019$168.80M+42.0%
Q4 FY2018Dec 31, 2018$222.80M+45.1%
Q3 FY2018Sep 30, 2018$168.60M+32.8%
Q2 FY2018Jun 30, 2018$153.60M+30.7%
Q1 FY2018Mar 31, 2018$118.90M+26.4%
Q4 FY2017Dec 31, 2017$153.50M+31.5%
Q3 FY2017Sep 30, 2017$127.00M–
Q2 FY2017Jun 30, 2017$117.50M–
Q1 FY2017Mar 31, 2017$94.10M–
Q4 FY2016Dec 31, 2016$116.70M–

More DexCom figures

See a number that looks wrong?